Transaction · 0001231919-26-001503

Venrock Healthcare Capital Partners III, L.P.

Venrock Healthcare Capital Partners III, L.P., 10%, reported an open-market or private purchase at Lycia Therapeutics, Inc. involving 8261.000000 shares for an estimated $222799.17. Reported holdings after the transaction were 6785437.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code P10%
LYCALycia Therapeutics, Inc.
Disclosed value$222kShares × reported price
Shares traded8.26k$26.97 per share
Holdings after6.78MIndirect · By Funds
% of reported position traded0.12%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 6,777,176 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

LYCA price since this filing

Daily closing prices, with the filing date and available return windows
LYCA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001231919-26-001503
Common Stock
Transaction date
Oct 26, 2026
Filed Oct 27, 2026, 10:38 PM · 1d delay
Shares
8,261 sh
$26.97 per share
Estimated value
$222k
Computed from shares × price
Holdings after
6,785,437 sh
Indirect · By Funds

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Buy Repeat Buyer 10% Owner Buy
Filing-only score

+42 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • ten_percent_owner_buy+4 points

    is_ten_percent_owner = true

    10% beneficial owner open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • repeat_buyer+8 points

    repeat-buyer signal matched

    Same insider bought again within the configured window.
  • timely_filing+4 points

    reporting_delay_days = 1

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    Consists of (i) 11,163 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 1,118 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 12,279 shares held…

  2. F2

    The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.00 to $25.99 inclusive. The Reporting Persons undertake…

  3. F3

    VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah…

  4. F4

    VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and m…

  5. F5

    Consists of (i) 12,898 shares held by VHCP3; (ii) 1,292 shares held by VHCP Co-3; and (iii) 14,189 shares held by VHCP EG.

  6. F6

    The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.00 to $26.25 inclusive. The Reporting Persons undertake…

  7. F7

    Consists of (i) 24,061 shares held by VHCP3; (ii) 2,410 shares held by VHCP Co-3; and (iii) 26,468 shares held by VHCP EG.

  8. F8

    Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; (iii) 3,216,639 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P.…

  9. F9

    Each share of Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.221793422 basis upon the closing of the Issuer's ini…

  10. F10

    Consists of (i) 852,540 shares held by VHCP3; (ii) 85,295 shares held by VHCP Co-3; (iii) 3,243,107 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

  11. F11

    VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and m…

  12. F12

    Consists of (i) 883,750 shares held by VHCP3; (ii) 88,472 shares held by VHCP Co-3; and (iii) 972,222 shares held by VHCP EG.

  13. F13

    Consists of (i) 1,736,290 shares held by VHCP3; (ii) 173,767 shares held by VHCP Co-3; (iii) 4,215,329 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

  14. F14

    Consists of (i) 3,755 shares held by VHCP3; (ii) 376 shares held by VHCP Co-3; and (iii) 4,130 shares held by VHCP EG.

  15. F15

    The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.82 to $27.00 inclusive. The Reporting Persons undertake…

  16. F16

    Consists of (i) 1,740,045 shares held by VHCP3; (ii) 174,143 shares held by VHCP Co-3; (iii) 4,219,459 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

  17. F17

    Consists of (i) 3,967 shares held by VHCP3; (ii) 397 shares held by VHCP Co-3; and (iii) 4,365 shares held by VHCP EG.

  18. F18

    The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.28 to $26.27 inclusive. The Reporting Persons undertake…

  19. F19

    Consists of (i) 1,744,012 shares held by VHCP3; (ii) 174,540 shares held by VHCP Co-3; (iii) 4,223,824 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

  20. F20

    Consists of (i) 14,120 shares held by VHCP3; (ii) 1,414 shares held by VHCP Co-3; and (iii) 15,533 shares held by VHCP EG.

  21. F21

    The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.28 to $27.00 inclusive. The Reporting Persons undertake…

  22. F22

    Consists of (i) 1,758,132 shares held by VHCP3; (ii) 175,954 shares held by VHCP Co-3; (iii) 4,239,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

  23. F23

    Consists of (i) 3,735,368 shares held by VHCP3; (ii) 373,708 shares held by VHCP Co-3; and (iii) 13,033,502 shares held by VHCP EG.

  24. F24

    Consists of (i) 828,479 shares held by VHCP3; (ii) 82,885 shares held by VHCP Co-3; and (iii) 2,890,744 shares held by VHCP EG.

  25. F25

    Consists of (i) 1,469,363 shares held by VHCP EG and (ii) 2,938,728

  26. shares held by VHCP XP.

  27. F26

    Consists of (i) 325,895 shares held by VHCP EG and (ii) 651,790 shares held by VHCP XP.

Original filing · 0001231919-26-001503
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

LYCA